DeepHealth is growing their AI solution portfolio. They already had AI solutions for lung cancer (after the acquisition of Aidence), prostate cancer (after the acquisition of Quantib), and breast cancer (FDA only). Now they have added another breast cancer AI solution through the acquisition of the British company Kheiron Medical Technologies.
From a technology perspective, Kheiron’s CE-marked AI solution Mia, which has regulatory clearance as an independent reader for 2D mammography, complements DeepHealth’s SmartMammo™ suite, which incorporates FDA-cleared and validated 3D mammography (DBT) clinical AI technology. With this acquisition, DeepHealth aims to strengthen its position in Europe by combining the capabilities of its 3D-focused SmartMammo, tailored for the U.S. market, with Kheiron’s 2D-focused Mia, designed for the European market.
Press release.